Cite
HARVARD Citation
Morabito, F. et al. (2021). TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American journal of hematology. 96 (8), pp. E306-E310. [Online].